Posttranscriptional deregulation of signaling pathways in meningioma subtypes by differential expression of miRNAs

Neuro-Oncology

Volumn 17, Issue 9, 2015, Pages 1250-1260

  Ludwig, Nicole ^a   Kim, Yoo Jin ^a   Mueller, Sabine C ^a,b   Backes, Christina ^a,b   Werner, Tamara V ^a   Galata, Valentina ^a,b   Sartorius, Elke ^a   Bohle, Rainer M ^a   Keller, Andreas ^b   Meese, Eckart ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

histological subtypes; meningioma; miRNA; qRT PCR

Indexed keywords

MICRORNA; MICRORNA 195; MICRORNA 222; MICRORNA 34A; MICRORNA 376C; MICRORNA 497; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; WNT PROTEIN; TUMOR MARKER;

ARTICLE; CANCER GRADING; COMPUTER MODEL; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE TARGETING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MENINGIOMA; MICROARRAY ANALYSIS; PHENOTYPE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; VALIDATION PROCESS; DISEASE COURSE; METABOLISM; PATHOLOGY; RNA PROCESSING; SIGNAL TRANSDUCTION;

BIOMARKERS, TUMOR; DISEASE PROGRESSION; HUMANS; MENINGEAL NEOPLASMS; MENINGIOMA; MICROARRAY ANALYSIS; MICRORNAS; NEOPLASM GRADING; RNA PROCESSING, POST-TRANSCRIPTIONAL; SIGNAL TRANSDUCTION;

EID: 84940740291     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov014     Document Type: Article

References (50)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281-297.
2. Cheng Q, Yi B, Wang A, et al. Exploring and exploiting the fundamental role of microRNAs in tumor pathogenesis. Onco Targets Ther. 2013;6:1675-1684.
3. Perry ALD, Scheithauer BW, Budka H, et al. Meningiomas. In: Louis DNOH, Wiestler OD, Cavenee WK, eds. WHO Classification of Tumors of the Central Nervous System. Lyon: IARC press; 2007: 164-172.
4. Stessin AM, Schwartz A, Judanin G, et al. Does adjuvant external-beam radiotherapy improve outcomes for nonbenign meningiomas? A Surveillance, Epidemiology, and End Results (SEER)-based analysis. J Neurosurg. 2012;117(4):669-675.
5. Perry A, Gutmann DH, Reifenberger G. Molecular pathogenesis of meningiomas. J Neurooncol. 2004;70(2):183-202.
6. Durand A, Champier J, Jouvet A, et al. Expression of c-Myc, neurofibromatosis type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: relation to grades or histotypes. Clin Neuropathol. 2008;27(5):334-345.
7. Ragel BT, Jensen RL. Aberrant signaling pathways in meningiomas. J Neurooncol. 2010;99(3):315-324.
8. Pecina-Slaus N, Cicvara-Pecina T, Kafka A. Epithelialto-mesenchymal transition: possible role in meningiomas. Front Biosci (Elite Ed). 2012;4:889-896.
9. Kliese N, Gobrecht P, Pachow D, et al. miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells. Oncogene. 2013; 32(39):4712-4720.
10. Saydam O, Shen Y, Wurdinger T, et al. Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway. Mol Cell Biol. 2009;29(21):5923-5940.
11. Zhi F, Zhou G, Wang S, et al. A microRNA expression signature predicts meningioma recurrence. Int J Cancer. 2013;132(1): 128-136.
12. Senol O, Schaaij-Visser TB, Erkan EP, et al. miR-200a-mediated suppression of non-muscle heavy chain IIb inhibits meningioma cell migration and tumor growth in vivo. Oncogene. 2014; doi: 10.1038/onc.2014.120. [Epub ahead of print].
13. R Development Core Team R. A Language and Environment for Statistical Computing. Vienna, Austria; 2010.
14. Hsu SD, Tseng YT, Shrestha S, et al. miRTarBase update 2014: an information resource for experimentally validated miRNA-target interactions. Nucleic Acids Res. 2014;42(Database issue):D78-D85.
15. Wang X. miRDB: a microRNA target prediction and functional annotation database with a wiki interface. RNA. 2008;14(6): 1012-1017.
16. Serna E, Morales JM, Mata M, et al. Gene expression profiles of metabolic aggressiveness and tumor recurrence in benign meningioma. PloS One. 2013;8(6):e67291.
17. Sharma S, Ray S, Mukherjee S, et al. Multipronged quantitative proteomic analyses indicate modulation of various signal transduction pathways in human meningiomas. Proteomics. 2015;15(2-3):394-407.
18. Backes C, Keller A, Kuentzer J, et al. GeneTrail-advanced gene set enrichment analysis. Nucleic Acids Res. 2007;35(Web Server issue):W186-W192.
19. Wang Y, Li W, Zang X, et al. MicroRNA-204-5p regulates epithelialto-mesenchymal transition during human posterior capsule opacification by targeting SMAD4. Invest Ophthalmol Vis Sci. 2013;54(1):323-332.
20. D'Amato NC, Howe EN, Richer JK. MicroRNA regulation of epithelial plasticity in cancer. Cancer Lett. 2013;341(1):46-55.
21. Lee Y, Liu J, Patel S, et al. Genomic landscape of meningiomas. Brain Pathol. 2010;20(4):751-762.
22. Zhang X, Gejman R, Mahta A, et al. Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression. Cancer Res. 2010; 70(6):2350-2358.
23. Haga CL, Phinney DG. MicroRNAs in the imprinted DLK1-DIO3 region repress the epithelial-to-mesenchymal transition by targeting the TWIST1 protein signaling network. J Biol Chem. 2012;287(51):42695-42707.
24. Luk JM, Burchard J, Zhang C, et al. DLK1-DIO3 genomic imprinted microRNA cluster at 14q32.2 defines a stemlike subtype of hepatocellular carcinoma associated with poor survival. J Biol Chem. 2011;286(35):30706-30713.
25. Laddha SV, Nayak S, Paul D, et al. Genome-wide analysis reveals downregulation of miR-379/miR-656 cluster in human cancers. Biol Direct. 2013;8:10.
26. Haller F, von Heydebreck A, Zhang JD, et al. Localization- and mutation-dependent microRNA (miRNA) expression signatures in gastrointestinal stromal tumours (GISTs), with a cluster of co-expressed miRNAs located at 14q32.31. J Pathol. 2010;220(1): 71-86.
27. Gattolliat CH, Thomas L, Ciafre SA, et al. Expression of miR-487b and miR-410 encoded by 14q32.31 locus is a prognostic marker in neuroblastoma. Br J Cancer. 2011;105(9):1352-1361.
28. Murakami M, Hashimoto N, Takahashi Y, et al. A consistent region of deletion on 1p36 in meningiomas: identification and relation to malignant progression. Cancer Genet Cytogenet. 2003;140(2): 99-106.
29. Brunner EC, Romeike BF, Jung M, et al. Altered expression of beta-catenin/E-cadherin in meningiomas. Histopathology. 2006; 49(2):178-187.
30. Zhou K, Wang G, Wang Y, et al. The potential involvement of E-cadherin and beta-catenins in meningioma. PloS One. 2010; 5(6):e11231.
31. Wang X, Gong Y, Wang D, et al. Analysis of gene expression profiling in meningioma: deregulated signaling pathways associated with meningioma and EGFL6 overexpression in benign meningioma tissue and serum. PloS One. 2012;7(12):e52707.
32. Lapham A, Adams JE, Paterson A, et al. The Bcl-w promoter is activated by beta-catenin/TCF4 in human colorectal carcinoma cells. Gene. 2009;432(1-2):112-117.
33. Zhang X, Gaspard JP, Chung DC. Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res. 2001;61(16):6050-6054.
34. Mann B, Gelos M, Siedow A, et al. Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci U S A. 1999;96(4): 1603-1608.
35. Shtutman M, Zhurinsky J, Simcha I, et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A. 1999;96(10):5522-5527.
36. Hirano M, Hashimoto S, Yonemura S, et al. EPB41L5 functions to post-transcriptionally regulate cadherin and integrin during epithelial-mesenchymal transition. J Cell Biol. 2008;182(6): 1217-1230.
37. Johnson MD, Okediji E, Woodard A. Transforming growth factor-beta effects on meningioma cell proliferation and signal transduction pathways. J Neurooncol. 2004;66(1-2):9-16.
38. Wendt MK, Tian M, Schiemann WP. Deconstructing the mechanisms and consequences of TGF-beta-induced EMT during cancer progression. Cell Tissue Res. 2012;347(1):85-101.
39. Tang Y, Katuri V, Dillner A, et al. Disruption of transforming growth factor-beta signaling in ELF beta-spectrin-deficient mice. Science. 2003;299(5606):574-577.
40. Chen Y, Yu P, Lu D, et al. A novel isoform of beta-spectrin II localizes to cerebellar Purkinje-cell bodies and interacts with neurofibromatosis type 2 gene product schwannomin. J Mol Neurosci. 2001;17(1):59-70.
41. Robb VA, Gerber MA, Hart-Mahon EK, et al. Membrane localization of the U2 domain of protein 4.1B is necessary and sufficient for meningioma growth suppression. Oncogene. 2005;24(11): 1946-1957.
42. Wu YY, Peck K, Chang YL, et al. SCUBE3 is an endogenous TGF-beta receptor ligand and regulates the epithelial-mesenchymal transition in lung cancer. Oncogene. 2011;30(34):3682-3693.
43. Wheeler M, Domin J. Recruitment of the class II phosphoinositide 3-kinase C2beta to the epidermal growth factor receptor: role of Grb2. Mol Cell Biol. 2001;21(19):6660-6667.
44. Mawrin C, Sasse T, Kirches E, et al. Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas. Clin Cancer Res. 2005;11(11):4074-4082.
45. Lamszus K, Lengler U, Schmidt NO, et al. Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy. Neurosurgery. 2000;46(4):938-947; discussion 947-948.
46. Lee SH, Lee YS, Hong YG, et al. Significance of COX-2 and VEGF expression in histopathologic grading and invasiveness of meningiomas. APMIS. 2014;122(1):16-24.
47. Monleon D, Morales JM, Gonzalez-Segura A, et al. Metabolic aggressiveness in benign meningiomas with chromosomal instabilities. Cancer Res. 2010;70(21):8426-8434.
48. Jiang J, Lin C, Liu N, et al. The expression of fatty acid metabolism-associated proteins is correlated with the prognosis of meningiomas. APMIS. 2013;121(10):997-1003.
49. Haase D, Schmidl S, Ewald C, et al. Fatty acid synthase as a novel target for meningioma therapy. Neuro Oncol. 2010;12(8): 844-854.
50. Pescador N, Villar D, Cifuentes D, et al. Hypoxia promotes glycogen accumulation through hypoxia inducible factor (HIF)-mediated induction of glycogen synthase 1. PloS One. 2010;5(3):e9644.